Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.37 USD | +4.88% | -8.21% | +14.26% |
Financials (USD)
Sales 2024 * | 200K | Sales 2025 * | 200K | Capitalization | 27.8M |
---|---|---|---|---|---|
Net income 2024 * | -18M | Net income 2025 * | -23M | EV / Sales 2024 * | 139 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 139 x |
P/E ratio 2024 * |
-1.97
x | P/E ratio 2025 * |
-3.28
x | Employees | 7 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.5% |
Latest transcript on Aprea Therapeutics, Inc.
1 day | +4.88% | ||
1 week | -8.21% | ||
Current month | -19.73% | ||
1 month | -11.73% | ||
3 months | -4.11% | ||
6 months | +37.52% | ||
Current year | +14.26% |
Managers | Title | Age | Since |
---|---|---|---|
Oren Gilad
CEO | Chief Executive Officer | 56 | 22-04-30 |
John Hamill
DFI | Director of Finance/CFO | 60 | 23-01-29 |
Zeev Weiss
PRN | Corporate Officer/Principal | 62 | 22-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernd Seizinger
BRD | Director/Board Member | 67 | 14-12-31 |
John Henneman
BRD | Director/Board Member | 62 | 19-07-31 |
Rifat Pamukcu
BRD | Director/Board Member | 66 | 22-04-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-22 | 5.12 | -4.30% | 11,827 |
24-04-19 | 5.35 | -4.63% | 7,291 |
24-04-18 | 5.61 | -2.09% | 998 |
24-04-17 | 5.73 | -2.05% | 2,294 |
24-04-16 | 5.85 | -0.85% | 5,097 |
Delayed Quote Nasdaq, April 23, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.26% | 27.8M | |
+3.13% | 42.11B | |
+48.83% | 40.08B | |
+8.49% | 40B | |
-10.82% | 26.87B | |
+8.26% | 24.58B | |
-23.69% | 18.44B | |
+1.58% | 11.94B | |
+32.83% | 11.66B | |
+6.63% | 11.01B |
- Stock Market
- Equities
- APRE Stock